GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (OTCPK:ONCWF) » Definitions » EV-to-FCF

ONCWF (Oncolytics Biotech) EV-to-FCF : 0.00 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Oncolytics Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oncolytics Biotech's Enterprise Value is $0.00 Mil. Oncolytics Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-13.71 Mil. Therefore, Oncolytics Biotech's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Oncolytics Biotech's EV-to-FCF or its related term are showing as below:

ONCWF' s EV-to-FCF Range Over the Past 10 Years
Min: -9.85   Med: 0   Max: 0
Current: -4

ONCWF's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs ONCWF: -4.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Oncolytics Biotech's stock price is $0.0046. Oncolytics Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.000. Therefore, Oncolytics Biotech's PE Ratio (TTM) for today is N/A.


Oncolytics Biotech EV-to-FCF Historical Data

The historical data trend for Oncolytics Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech EV-to-FCF Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.26 -4.91 -2.45 -4.46 -3.47

Oncolytics Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.32 -3.47 -2.87 -4.07 -3.96

Competitive Comparison of Oncolytics Biotech's EV-to-FCF

For the Biotechnology subindustry, Oncolytics Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's EV-to-FCF falls into.



Oncolytics Biotech EV-to-FCF Calculation

Oncolytics Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-13.708
=0.00

Oncolytics Biotech's current Enterprise Value is $0.00 Mil.
Oncolytics Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncolytics Biotech  (OTCPK:ONCWF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Oncolytics Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0046/0.000
=N/A

Oncolytics Biotech's share price for today is $0.0046.
Oncolytics Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Oncolytics Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Oncolytics Biotech Headlines